300
Participants
Start Date
October 31, 2015
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Selinexor
Oral tablets
Dexamethasone
Oral tablets
Lenalidomide
Oral capsule
Pomalidomide
Oral tablets
Bortezomib
Subcutaneous Injection (single use vial)
Daratumumab
Intravenous Infusion
Carfilzomib
Intravenous infusion
Ixazomib
Oral capsule
Elotuzumab
Intravenous infusion
Clarithromycin
Tablets
Belantamab Mafodotin
Intravenous infusion
Mezigdomide
Oral Capsules
COMPLETED
Columbia University, New York
COMPLETED
Weill Cornell Medicine, New York
RECRUITING
University of North Carolina - Chapel Hill Comprehensive Cancer Center, Chapel Hill
RECRUITING
Duke Institute of Cancer/ Duke University, Durham
RECRUITING
Sarah Cannon- Tennessee Oncology Nashville, Nashville
RECRUITING
University of Wisconsin School of Medicine and Public Health, Madison
WITHDRAWN
University of Nebraska Medical Center, Omaha
WITHDRAWN
Sarah Cannon-Colorado Blood Cancer Institute, Denver
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
WITHDRAWN
Swedish Cancer Institute, Seattle
RECRUITING
Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
RECRUITING
Wilmot Cancer Center/ University of Rochester, Rochester
WITHDRAWN
Tom Baker Cancer Center/Alberta Health Services, Calgary
WITHDRAWN
Cross Cancer Institute / University of Alberta, Edmonton
WITHDRAWN
Vancouver General Hospital, Vancouver
ACTIVE_NOT_RECRUITING
Cancer Care Manitoba, Winnipeg
COMPLETED
Memorial Hospital of Newfoundland, St. John's
RECRUITING
Queen Elizabeth II Health Sciences Center, Halifax
RECRUITING
Princess Margaret Cancer Centre, Toronto
COMPLETED
Maisonneuve-Rosemont Hospital, Montreal
COMPLETED
Royal Victoria Hospital / McGill University, Montreal
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Karyopharm Therapeutics Inc
INDUSTRY